Russian Federation
UDK 61 Медицина. Охрана здоровья
The main advantage of targeted therapy for cancer is the unique ability to mobilize the body's own immune system. Stimulation of the immune response leads to activation of internal protective functions that prevent angiogenesis and apoptosis of cancer cells. In addition, drugs that modify the biological reaction accelerate the process of tissue regeneration and the replacement of pathogenic cells with genetically normal ones.
targeted therapy, genetic engineering therapy, antitumor gene therapy, apoptosis, angiogenesis oncology.
1. Alekseev B. Ya. Kalpinskiy A. S. «Targetnaya terapiya rasprostranennogo raka pochki sunitinibom». Russkiy medicinskiy zhurnal. - 2008. - № 27. - S. 1824-1828.
2. Zhukova L. G. «Sovremennye vozmozhnosti i perspektivy targetnoy terapii pri rake molochnoy zhelezy». Prakticheskaya onkologiya. - 2010. - T. 11, № 3. - S. 182-191.
3. Imyanitov E. N. «Obschie svedeniya o targetnoy terapii». Prakticheskaya onkologiya. - 2010. - T. 11, № 3. - S. 123-130.
4. D.B. Korman (Institut biohimicheskoy fiziki RAN im. N.M. Emanuelya ). Lekciya 3. S 1-7.
5. Rosenberg S.A. Principles of cancer management: biologic therapy. Cancer: Principles & Practice of Oncology, Fifth Edition / Ed. by Vincent T. DeVita, Jr. M.D., Samuel Hellman, M.D., Steven A. Rosenberg, M.D. Ph.D.; Chapter 1. - 1997. - Philadelphia: LippincottRaven Publishers, 1997. - P.349373.
6. Jungans R.P., Sgouros G., Scheinberg D. Antibodybased immunotherapies for cancer // Cancer chemotherapy and biotherapy, 2nd edit. / Ed. by Bruce Chabner and Dan Longo. - Philadelphia: LippincottRaven Publishers., 1996. - P. 655689.
7. Novik A. V. «Targetnaya terapiya pri limfoproliferativnyh zabolevaniyah». Prakticheskaya onkologiya. - 2010. - T. 11, № 3. - S. 131-142.
8. Nemcova E.R., Bezborodova O.A., Yakubovskaya R.I., Kaprin A.D. Genno-terapevticheskie preparaty v onkologii: sovremennoe sostoyanie. Issledovaniya i praktika v medicine. 2016; 3(4): 33-43. DOI:https://doi.org/10.17709/2409-2231-2016-3-4-4.
9. Novik A. V., Moiseenko V. M. «Teoreticheskie predposylki ad'yuvantnoy terapii zlokachestvennyh opuholey». Prakticheskaya onkologiya. - 2007. - T. 8, № 3. - S. 109-117.
10. Moiseenko F.V. s soavt. Rol' gefitiniba v lechenii bol'nyh nemelkokletochnym rakom legkogo s mutaciey v gene receptora epidermal'nogo faktora rosta. Sovremennaya onkologiya, 2011, 3, S. 50-54.
11. Azzoli C.G., et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol. 2009. 27, P. 6251-6266.
12. European Medicines Agency Iressa: Gefitinib - EPAR summary for the public. http://www.emea.europa.eu/humandocs/PDFs/EPAR/iressa/H-1016-en1.pdf.
13. Davydov M.I., Aksel' E.M. Zabolevaemost' zlokachestvennymi novoobrazovaniyami i smertnost' ot nih naseleniya stran SNG v 2002 g., M. - 2002.
14. Matveev V.B. Targetnaya terapiya rasprostranennogo raka pochki: problema vybora preparata na primere mul'tikinaznyh ingibitorov. "Konsilium Medikum" Tom 11, № 3 (2009). S. 23-25.
15. Perevodchikova I.N. Targetnye preparaty i ih mesto v sovremennoy terapii opuholevyh processov // Klinicheskaya onkogematologiya. - 2009. - T.2, №4. - S. 367-373.
16. Shepherd F., Pereira J., Cinleanu T.E. et al. Erlotinib in previously treated non-small cell lung cancer // New England Journal of Medicine. - 2005. - V. 353. - P. 123-132.
17. Gosudarstvennyy reest lekarstvennyh sredst. Iressa. Registracionnoe udostoverenie. GRLM, 2009.
18. Stat'ya «Targetnaya terapiya v onkologii». Medicinskiy centr im. Rabina. https://rabin-medical.org.il/onkologiya/procedury/biologicheskie-preparaty-pri-lechenii-raka/
19. Onkologicheskaya statistika (tradicionnye metody, novye informacionnye tehnologii). Rukovodstvo dlya vrachey. FGU NII onkologii im. N.N. Petrova Populyacionnyy rakovyy registr Sankt-Peterburga ( № 221 IACR). V.M. Merabishvili.
20. Hvastunov R.A., Skrypnikova G.V., Usachev A.A. Targetnaya terapiya v onkologi // Lekarstvennyy vestnik. - 2014. - T. 8. - №4(56). -S. 3-10.
21. Motzer R.J., Bander N.H., Nanus D.M. Renal cell carcinoma review article // N. Engl. J. Med. - 1996. - Vol.12. - P.865 875.
22. Bukowski R.M. Natural history and therapy of metastatic renal cell carcinoma. The role of interleukin2 // Cancer. - 1997. - Vol.80. - P.1198-11220.
